Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q28085614)
Watch
English
Biologics in asthma--the next step toward personalized treatment
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
review article
1 reference
stated in
Europe PubMed Central
title
Biologics in asthma--the next step toward personalized treatment
(English)
1 reference
stated in
PubMed
main subject
asthma
0 references
author
William W Busse
series ordinal
2
object named as
William W. Busse
1 reference
stated in
Crossref
author name string
Jared Darveaux
series ordinal
1
1 reference
stated in
Crossref
language of work or name
English
1 reference
stated in
PubMed
publication date
2015
1 reference
stated in
PubMed
published in
The Journal of Allergy and Clinical Immunology: In Practice
1 reference
stated in
PubMed
volume
3
1 reference
stated in
PubMed
issue
2
1 reference
stated in
PubMed
page(s)
152-60; quiz 161
1 reference
stated in
PubMed
cites work
Omalizumab for asthma in adults and children
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
20 March 2017
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
20 March 2017
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
20 March 2017
Reslizumab for Poorly Controlled, Eosinophilic Asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
7 April 2017
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
7 April 2017
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
The potential of biologics for the treatment of asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Targeting interleukin-4 in asthma: lost in translation?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab and the risk of malignancy: results from a pooled analysis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Lebrikizumab treatment in adults with asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
IL-33 and Airway Inflammation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Mepolizumab and exacerbations of refractory eosinophilic asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
The cytokine network in asthma and chronic obstructive pulmonary disease
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
A mechanism for the initiation of allergen-induced T helper type 2 responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab : other indications and unanswered questions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Anti-interleukin-4 therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Omalizumab treatment downregulates dendritic cell FcepsilonRI expression
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
29 September 2017
Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
2 June 2018
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
20 June 2018
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Dupilumab in persistent asthma with elevated eosinophil levels
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Choosing asthma step-up care
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Interleukin-13 in asthma pathogenesis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4774509
retrieved
27 November 2018
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Study of infliximab treatment in asthma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Inhibition of allergic reactions with antibodies to IgE
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
High prevalence of skin test positivity in severe or difficult-to-treat asthma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25754716
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1016/J.JAIP.2014.09.014
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
332405
OpenCitations bibliographic resource ID
332405
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
332405
PMCID
4774509
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
332405
PubMed ID
25754716
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
332405
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
